Physician profile
John C Shehan
NPI 1902800287
$3,151.19
in general payments reported to CMS, 2019-2025
26 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $468 · 2021: $774 · 2022: $221 · 2023: $450 · 2024: $327 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.25 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $907.71 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $577.86 | 2021-2025 | Xywav |
| Ethicon INC. | $356.82 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $214.03 | 2023 | Acthar |
| Glaxosmithkline, LLC. | $184.62 | 2019-2024 | Trelegy Ellipta |
| Itamar Medical INC | $114.62 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $95.19 | 2024-2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $78.75 | 2019 | |
| Electromed, INC. | $72.70 | 2019-2025 | Smartvest |
| Inspire Medical Systems, INC. | $71.79 | 2025 | Inspire |
| Genentech USA, INC. | $49.48 | 2019-2020 | |
| Philips North America LLC | $47.25 | 2022-2025 | Vest Therapy Und |
| Harmony Biosciences LLC | $45.69 | 2024-2025 | |
| Amgen INC. | $42.49 | 2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $40.30 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $36.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.69 | 2023-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Genzyme Corporation | $31.46 | 2019-2024 | |
| Insmed, INC. | $29.90 | 2019-2025 | Arikayce |
| United Therapeutics Corporation | $27.48 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.87 | 2024 | Glassia |
| Zoll Respicardia, INC. | $16.82 | 2024 | Remede System |
| Pfizer INC. | $16.13 | 2025 | |
| La Jolla Pharmaceutical Company | $15.53 | 2025 | Giapreza |
| Novartis Pharmaceuticals Corporation | $13.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.09 | 2024 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.